LB-100 is a water-soluble protein phosphatase 2A (PP2A) inhibitor used to suppress PP2A activity in cancer cells (e.g., BxPc-3, Panc-1, and SW1990), inhibit tumor cell proliferation, enhance intracellular doxorubicin concentration and chemosensitivity to doxorubicin, promote HIF-1α-VEGF-mediated angiogenesis by increasing VEGF secretion, and improve the efficacy of doxorubicin in pancreatic cancer xenograft models by increasing tumor microvessel density and blood flow velocity.